Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia
Ciceri Fabio
80 participants
Feb 22, 2025
OBSERVATIONAL
Conditions
Summary
The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.
Eligibility
Inclusion Criteria7
- Any gender,
- Adults (\>18 years old),
- New suspect diagnosis of acute myeloid leukemia (ELN2022 Criteria)
- Capable of comprehend the study and the consent form,
- Willing to sign the informed consent for the study.
- For the retrospective population we will select:
- biological samples (BM Biopsies, BM Aspirates and PB) already banked upon research purpose informed consent and collected from the 01/06/2006 up to 01/06/2024 from adults patients with diagnosis of acute myeloid leukemia according to ELN2017 Criteria.
Exclusion Criteria2
- Pediatric patients (\<18 years old),
- Patients unable or unwilling to sign the informed consent.
Interventions
All the procedures in Study will be conducted as per Clinical practice for the pathology and all the samples will be collected according to ELN guidelines. There are no additional procedures but will be additionally collected up 20ml of peripheral blood and up to 15ml of Bone Marrow Aspirate at the same time of clinically indicated diagnostic procedures.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06535113